REPL SHAREHOLDER ALERT: Replimune Group Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Kirby McInerney LLP announced an investigation into Replimune Group regarding potential violations of federal securities laws related to the FDA's review of its drug RP1.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.